Try a new search

Format these results:

Searched for:



Total Results:


Contemporary practice patterns and outcomes of systemic thrombolysis in acute pulmonary embolism

Gayen, Shameek; Katz, Alyson; Dikengil, Fusun; Kwok, Benjamin; Zheng, Matthew; Goldenberg, Ronald; Jamin, Catherine; Yuriditsky, Eugene; Bashir, Riyaz; Lakhter, Vladimir; Panaro, Joseph; Cohen, Gary; Mohrien, Kerry; Rali, Parth; Brosnahan, Shari B
OBJECTIVE:Although systemic thrombolysis (ST) is the standard of care in the treatment of high-risk pulmonary embolism (PE), large variations in real-world usage exist, including its use to treat intermediate-risk PE. A paucity of data is available to define the outcomes and practice patterns of the ST dose, duration, and treatment of presumed and imaging-confirmed PE. METHODS:We performed a multicenter retrospective study to evaluate the real-world practice patterns of ST use in the setting of acute PE (presumed vs imaging-confirmed intermediate- and high-risk PE). Patients who had received tissue plasminogen activator for PE between 2017 and 2019 were included. We compared the baseline clinical characteristics, tissue plasminogen activator practice patterns, and outcomes for patients with confirmed vs presumed PE. RESULTS:A total of 104 patients had received ST for PE: 52 with confirmed PE and 52 with presumed PE. Significantly more patients who had been treated for presumed PE had experienced cardiac arrest (n = 47; 90%) compared with those with confirmed PE (n = 23; 44%; P < .01). Survival to hospital discharge was 65% for the patients with confirmed PE vs 6% for those with presumed PE (P < .01). The use of ST was contraindicated for 56% of the patients with confirmed PE, with major bleeding in 26% but no intracranial hemorrhage. CONCLUSIONS:The in-hospital mortality of patients with confirmed acute PE has remained high (35%) in contemporary practice for those treated with ST. A large proportion of these patients had had contraindications to ST, and the rates of major bleeding were significant. Those with confirmed PE had had a higher survival rate compared with those with presumed PE, including those with cardiac arrest. This observation suggests a limited role for empiric thrombolysis in cardiac arrest situations.
PMID: 35714905
ISSN: 2213-3348
CID: 5282852

Pulmonary Pathology of End-Stage COVID-19 Disease in Explanted Lungs and Outcomes After Lung Transplantation

Flaifel, Abdallah; Kwok, Benjamin; Ko, Jane; Chang, Stephanie; Smith, Deane; Zhou, Fang; Chiriboga, Luis A; Zeck, Briana; Theise, Neil; Rudym, Darya; Lesko, Melissa; Angel, Luis; Moreira, Andre; Narula, Navneet
OBJECTIVES/OBJECTIVE:Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may develop end-stage lung disease requiring lung transplantation. We report the clinical course, pulmonary pathology with radiographic correlation, and outcomes after lung transplantation in three patients who developed chronic respiratory failure due to postacute sequelae of SARS-CoV-2 infection. METHODS:A retrospective histologic evaluation of explanted lungs due to coronavirus disease 2019 was performed. RESULTS:None of the patients had known prior pulmonary disease. The major pathologic findings in the lung explants were proliferative and fibrotic phases of diffuse alveolar damage, interstitial capillary neoangiogenesis, and mononuclear inflammation, specifically macrophages, with varying numbers of T and B lymphocytes. The fibrosis varied from early collagen deposition to more pronounced interstitial collagen deposition; however, pulmonary remodeling with honeycomb change was not present. Other findings included peribronchiolar metaplasia, microvascular thrombosis, recanalized thrombi in muscular arteries, and pleural adhesions. No patients had either recurrence of SARS-CoV-2 infection or allograft rejection following transplant at this time. CONCLUSIONS:The major pathologic findings in the lung explants of patients with SARS-CoV-2 infection suggest ongoing fibrosis, prominent macrophage infiltration, neoangiogenesis, and microvascular thrombosis. Characterization of pathologic findings could help develop novel management strategies.
PMID: 34999755
ISSN: 1943-7722
CID: 5118212

Microbial Signatures in Malignant Pleural Effusions [Meeting Abstract]

Kwok, B.; Wu, B. G.; Kocak, I. F.; Anwer, R.; Li, Y.; Goparaju, C.; Schluger, R.; Murthy, V.; Rafeq, S.; Bessich, J. L.; Tsay, J. J.; Pass, H. I.; Segal, L. N.
ISSN: 1073-449x
CID: 5266102

Pulmonary Embolism Response Team activation during the COVID-19 pandemic in a New York City Academic Hospital: a retrospective cohort analysis

Kwok, Benjamin; Brosnahan, Shari B; Amoroso, Nancy E; Goldenberg, Ronald M; Heyman, Brooke; Horowitz, James M; Jamin, Catherine; Sista, Akhilesh K; Smith, Deane E; Yuriditsky, Eugene; Maldonado, Thomas S
Coronavirus disease 2019 (COVID-19) is associated with increased rates of deep vein thrombosis (DVT) and pulmonary embolism (PE). Pulmonary Embolism Response Teams (PERT) have previously been associated with improved outcomes. We aimed to investigate whether PERT utilization, recommendations, and outcomes for patients diagnosed with acute PE changed during the COVID-19 pandemic. This is a retrospective cohort study of all adult patients with acute PE who received care at an academic hospital system in New York City between March 1st and April 30th, 2020. These patients were compared against historic controls between March 1st and April 30th, 2019. PE severity, PERT utilization, initial management, PERT recommendations, and outcomes were compared. There were more cases of PE during the pandemic (82 vs. 59), but less PERT activations (26.8% vs. 64.4%, p < 0.001) despite similar markers of PE severity. PERT recommendations were similar before and during the pandemic; anticoagulation was most recommended (89.5% vs. 86.4%, p = 0.70). During the pandemic, those with PERT activations were more likely to be female (63.6% vs. 31.7%, p = 0.01), have a history of DVT/PE (22.7% vs. 1.7%, p = 0.01), and to be SARS-CoV-2 PCR negative (68.2% vs. 38.3% p = 0.02). PERT activation during the pandemic is associated with decreased length of stay (7.7 ± 7.7 vs. 13.2 ± 12.7 days, p = 0.02). PERT utilization decreased during the COVID-19 pandemic and its activation was associated with different biases. PERT recommendations and outcomes were similar before and during the pandemic, and led to decreased length of stay during the pandemic.
PMID: 32910409
ISSN: 1573-742x
CID: 4589422

Lower Airway Microbiota Predicts Malignancy Recurrence of Surgically Resected Early-Stage Lung Cancer [Meeting Abstract]

Kwok, B.; Tsay, J. J.; Sulaiman, I; Wu, B. G.; Li, Y.; Pass, H., I; Segal, L. N.
ISSN: 1073-449x
CID: 5266092

Exercise-Induced Small Airway Dysfunction Detected by Oscillometry Uncovers Mechanisms for Unexplained Dyspnea [Meeting Abstract]

Sharpe, A. L.; Oppenheimer, B. W.; Goldring, R. M.; Sterman, D. H.; Addrizzo-Harris, D. J.; Weinstein, T.; Kwok, B.; Bohart, I.; Berger, K. I.
ISSN: 1073-449x
CID: 5266052

Thrombolytics in Cardiac Arrest: Is It Beneficial in Confirmed or Suspected PE? [Meeting Abstract]

Gayen, S.; Dikengil, F.; Zheng, M.; Katz, A.; Kwok, B.; Brosnahan, S.; Rali, P.
ISSN: 1073-449x
CID: 5266062

Time to Systemic Thrombolysis in Confirmed Massive Pulmonary Embolism in a Single Center [Meeting Abstract]

Kwok, B.; Katz, A.; Dikengil, F.; Gayen, S.; Zheng, M.; Rali, P.; Brosnahan, S. B.
ISSN: 1073-449x
CID: 5266072

Clot in Transit on Transesophageal Echocardiography in a Prone Patient with COVID-19 Acute Respiratory Distress Syndrome [Case Report]

Horowitz, James M; Yuriditsky, Eugene; Henderson, Ian J; Stachel, Maxine Wallis; Kwok, Benjamin; Saric, Muhamed
•The risk of thromboembolic events in COVID-19 is substantial•Pulmonary embolism should be considered in cases of clinical deterioration•Management of clot in transit is controversial.
PMID: 32426575
ISSN: 2468-6441
CID: 4444112

Alvimopan for the Prevention of Postoperative Ileus in Inflammatory Bowel Disease Patients

Jang, Janice; Kwok, Benjamin; Zhong, Hua; Xia, Yuhe; Grucela, Alexis; Bernstein, Mitchell; Remzi, Feza; Hudesman, David; Chen, Jingjing; Axelrad, Jordan; Chang, Shannon
BACKGROUND:Postoperative ileus (POI) is a temporary delay of coordinated intestinal peristalsis. Alvimopan, an oral peripherally acting mu-opioid receptor antagonist approved for accelerating gastrointestinal recovery, has never been studied specifically in patients with inflammatory bowel disease (IBD). AIM/OBJECTIVE:To investigate the efficacy of alvimopan in preventing POI among IBD patients. METHODS:A retrospective chart review was conducted on 246 IBD patients undergoing bowel surgery between 2012 and 2017. Data collected included demographics, IBD subtype, length of stay (LOS), postoperative gastrointestinal symptoms, and administration of alvimopan. The primary outcome was POI; secondary gastrointestinal recovery outcomes were: time to first flatus, time to first bowel movement, time to tolerating a liquid diet, time to tolerating solid food, and LOS. RESULTS:When compared with the control group, patients in the alvimopan group had shorter times to tolerating liquids and solids, first flatus, and first bowel movements (p < 0.01). LOS was shorter in the alvimopan group when compared with controls (p < 0.01). The overall incidence of POI was higher in controls than in the alvimopan group (p = 0.07). For laparoscopic surgeries, the incidence of POI was also higher in controls than in the alvimopan group (p < 0.01). On multivariable analysis, alvimopan significantly decreased time to all gastrointestinal recovery endpoints when compared to controls (p < 0.01). CONCLUSIONS:Alvimopan is effective in accelerating time to gastrointestinal recovery and reducing POI in IBD patients. While the benefits of alvimopan have been demonstrated previously, this is the first study of the efficacy of alvimopan in IBD patients.
PMID: 31522323
ISSN: 1573-2568
CID: 4097752